Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow

Nature Medicine

Volumn 7, Issue 4, 2001, Pages 452-458

  Feuerer, Markus ^a   Beckhove, Philipp ^a   Bai, Lianhua ^a   Solomayer, Erich Franz ^b   Bastert, Gunther ^b   Diel, Ingo J ^b   Pedain, Claudia ^b   Oberniedermayr, Michael ^c   Schirrmacher, Volker ^a   Umansky, Victor ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c StJosefs Krankenhaus Heidelberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; BREAST CANCER; CANCER THERAPY; CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED NOD; MICE, SCID; NECROSIS; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA;

EID: 0035048973     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/86523     Document Type: Article

References (45)

1. From synapses to immunological memory: The role of sustained T cell stimulation
2. Selecting and maintaining a diverse T-cell repertoire
3. On immunological memory
4. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
5. + T cells
6. + T cells to antigen stimulation in vivo
7. Factors controlling the turnover of T memory cells
8. Differential requirements for survival and proliferation of CD8 naive or memory T cells
9. Following the development of a CD4 T cell immune response in vivo: From activation to memory formation
10. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection
11. + immune T cells
12. Detection and clinical importance of micrometastatic disease
13. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients
14. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
15. Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies
16. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1
17. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice
18. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice
19. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
20. Prospective randomized trial of high-dose interleukin-2 alone or in conjuction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
21. A new era for cancer immunotherapy based on the genes that encode cancer antigens
22. Tumor specific CTL response requiring interactions of four different cell types and dual recognition of MHC class I and class II restricted tumor antigens
23. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of ist receptor
24. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
25. The making of a tumor rejection antigen
26. MUC1 epithelial tumor-mucin-based immunity and cancer vaccines
27. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
28. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
29. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages
30. Charcterization of circulating T cells specific for tumor-associated antigens in melanoma patients
31. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients
32. Memory B lymphocytes migrate to bone marrow in humans
33. Bone marrow contains virus-specific cytotoxic T lymphocytes
34. + T cells in mouse bone marrow. I. Increased activated/memory phenotype and altered TCR V-β repertoire
35. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and cell-associated viral RNA levels in distinct lymphoid compartments of SIVmac-infected rhesus monkeys
36. 4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen
37. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue
38. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1
39. Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leucocytes
40. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
41. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
42. Micrometastatic breast cancer cells in bone marrow at primary surgery - Prognostic value in comparison to nodal status
43. + memory T cells
44. Selective activation of Fas/FasL mediated cytotoxicity by a self-peptide